OMCAT
Menu
CANKADO initialized OMCAT
CANKADO initialized OMCAT – the worldwide largest trial in oncology based on Artificial Intelligence
Our aim is the development of an AI-based Incident Prediction Algorithm to Improve Cancer Patient Care and Patient Safety.
Core elements of OMCAT
OMCAT is an innovative clinical study for cancer patients with the aim of optimizing patient care. The prediction of negative therapy events, also known as serious adverse events, should enable early intervention and, if necessary, even the avoidance of the events in the future. To make this possible, OMCAT includes detailed documentation of these events through the digital health application (DiGA) PRO-React Onco.
After an extensive checking process by the Federal Institute for Drugs and Medical Devices (BfArM), PRO-React Onco has been approved in May 2021. Since then, prescriptions can be reimbursed by statutory health insurance.
Certifications
Clinical Evidence
Medical Device
High Data Security
DiGA Directory Admission
Core elements of OMCAT
OMCAT is an innovative clinical study for cancer patients with the aim of optimizing patient care. The prediction of negative therapy events, also known as serious adverse events, should enable early intervention and, if necessary, even the avoidance of the events in the future. To make this possible, OMCAT includes the detailed documentation of these events through the digital health application (DiGA) PRO-React Onco. This has already been comprehensively checked by the Federal Institute for Drugs and Medical Devices (BfArM). The examination covered aspects from data protection to the user-friendliness of the application.
Certifications
Clinical Evidence
A Medical Device
High Data Security
Official DiGA Application
Benefits for patients
Within OMCAT, patients benefit from:
- Symptom-specific behavioral instruction
- Longer duration of patient retention in therapy
- Enhanced patients satisfaction
- Up to 59% fewer serious adverse events
- A stabilized course of therapy through fewer dose reductions
In addition, by participating in OMCAT, patients can help improve future care and safety for cancer patients.
Benefits for healthcare professionals
In addition, by participating in OMCAT, healthcare professionals can help improve future patient care.
Medical professionals benefit from within OMCAT through
Earlier detection of serious adverse events
More efficient patient visits
Continuous and clear reports on the patient's disease progression
Situation-specific patient care
Artificial intelligence in OMCAT
OMCAT uses innovative methods and artificial intelligence to develop a predictive algorithm to optimize cancer patient care.
This should be in the future:
- The identification of risk patients
- The detection of adverse events earlier than of what is possible today
- The enabling of early interventions and the possible avoidance of of adverse events
- The increase of patients safety
Our Esteemed Steering Committee
OMCAT is advised by an international and interdisciplinary steering committee made up of experienced and renowned members.
Prof. Dr. Michael von Bergwelt
University Hospital Munich, LMU Munich, Germany
Prof. Dr. Fatima Cardoso
Champalimaud Clinical Center, Lisbon, Portugal
Prof. Dr. Nadia Harbeck
University Hospital Munich, LMU Munich, Germany
Prof. Dr. Sherko Kümmel
Clinical Center Essen (KUM), Essen, Germany
PD Dr. Peter Staib
St. Antonius Hospital, Eschweiler, Deutschland
Prof. Dr. Manfred Mitterer
Hospital Merano, Merano, Italy
Prof. Dr. Martin Nowak
Harvard University, Cambridge, MA, USA
Dr. Manfred Welslau
Oncology Aschaffenburg, Aschaffenburg, Germany
Prof. Dr. Clemens Wendtner
Clinic Schwabing, Munich, Germany
Prof. Dr. Rudolf Hess
University Hospital Mainz, Mainz, Germany
OMCAT Perimeter
Estimated Enrollment 166,000 Patients
Study Start
August 2022
Expected Study Completion December 2025
Interested to join the future of cancer care?
Contact
- +49 (0) 221 429 153 00
- 0800 - 0009212
- omcat@cankado.com